Combinations ; See Below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Dapsone | Cosmos Limited. | Cosmos Limited | 100mg | 100 | Tablet | per tablet | KES 240.00 |
| Dapsone | Biopharma Laboratories Ltd. | Maxim Pharmaceuticals Ltd | 100mg | 1000 | Tablet | per tablet | KES 3,500.00 |
| Dapsone More info | |
|---|---|
| Mode Of Action | Inhibition of bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). (This is a step in the biosynthesis of nucleic acids and proteins required by many bacteria). |
| Drug Indication | All types of leprosy (of value in dermatitis herpetiform), toxoplasmosis and mycetoma, malarial prophylaxis. |
| Precautions | Cardiac or pulmonary disease; anaemia (treat severe anaemia before starting); susceptibility to haemolysis including G6PD deficiency; avoid in acute porphyria; discontinue if severe lepra reactions occur. |
| Contra-Indications | Probenecid reduces excretion. |
| Side Effects | Tachycardia, CNS, Headache, insomnia, peripheral neuropathy, psychosis, vertigo, pyrexia (1%); suicide attempt, tonic-clonic movements.Bullous and exfoliative dermatitis, erythema multiforme, erythema nodosum, morbilliform and scarlatiniform reactions, phototoxicity, toxic epidermal necrolysis (TEN), urticaria.Blurred vision, nasopharyngitis,pharyngitis, severe pharyngitis.Abdominal pain, pancreatitis, severe vomiting.Agranulocytosis, hemolysis, hemolytic anemia. |
| Dosage | 1-2mg/kg daily. |
| Special Information | Mode of action of dapsone in reducing inflammation are not fully known |
| Pregnancy Category | Category B2 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Anti-Leprotic |